- Company
-
- Aifinyo AG
- Aixtron SE
- Berentzen Gruppe AG
- Brain Biotech AG
- Carl Zeiss Meditec AG
- Cherry SE
- Deutz AG
- Edag Engineering Group AG
- ElringKlinger AG
- Encavis AG
- Energiekontor AG
- Gerresheimer AG
- Hypoport SE
- Jost Werke SE
- Knaus Tabbert AG
- LEG Immobilien SE
- Mister Spex SE
- Mountain Alliance AG
- Mutares SE
- Nemetschek SE
- Rational AG
- RENK Group AG
- Schaltbau Holding AG
- SFC Energy AG
- Sixt SE
- Talanx AG
- USU Software AG
- Varta AG
- voxeljet AG
- Verve Group Se
- Wacker Chemie AG
- Zeal Network SE
- Presentations
- Sector
- Index
- About
- Blog
Gerresheimer AG Financial Results H1 2024 | Strong Growth & Strategic Investments
July 11, 2024-
23:20 
Investor Relations
Gerresheimer AG H1 2024: Key Takeaways
Overview of Q2 2024 Results
Join us for an in-depth video presentation with Guido Pickert, Head of Investor Relations at Gerresheimer, as he walks through the company’s robust financial performance for the first half of 2024. This presentation is essential for investors looking to understand the company’s trajectory and strategic focus.
Financial Highlights
Despite market challenges, Gerresheimer reported a notable 1.7% increase in organic revenue, reaching an impressive €968.5 million. This growth underscores the company’s resilience and ability to navigate market challenges effectively, providing reassurance to our investors.
Adjusted EBITDA
There was a commendable 2.9% improvement in adjusted EBITDA, amounting to €188.2 million. This improvement highlights the company’s efficient cost management and operational excellence.
Margins
The adjusted EBITDA margin stands robust at 19.4%, reflecting the company’s strong financial health and strategic initiatives.
Segment Performance
Plastics & Devices
Revenue Growth: This segment achieved a remarkable 9.9% increase in revenue, driven by innovative solutions and high demand.
Adjusted EBITDA Margin: The margin improved significantly to 25.5%, showcasing the segment’s efficiency and market leadership.
Primary Packaging Glass
Revenue Decline: Despite facing a 6.9% decline in revenue due to inventory effects in the pharmaceutical segment, the segment is poised for recovery.
Adjusted EBITDA Margin: The margin decreased to 17.4%, but the company remains optimistic about future performance with strategic adjustments.
Strategic Insights and Future Outlook
Gerresheimer’s strategic foresight is evident in its plans for the second half of 2024. The company anticipates a revitalized business climate, driven by the introduction of new production lines and a reduction in inventory effects. Gerresheimer confidently reaffirms its forecast for 2024 and 2025, expecting organic revenue growth between 5-10% and an adjusted EBITDA of €430-450 million, instilling confidence in our stakeholders.
Watch the Video Presentation
Watch the comprehensive video presentation to learn more about Gerresheimer’s financial journey and plans. Guido Pickert provides expert analysis and insights crucial for investors and stakeholders who want to stay informed about Gerresheimer’s market strategies and performance metrics.
About Gerresheimer
As a leading global partner for the pharma, biotech, and cosmetics industries, Gerresheimer is renowned for its innovative systems and solutions. With 35 production sites across 16 countries, Gerresheimer is committed to ensuring the safe delivery and administration of medications worldwide. The company’s dedication to quality and innovation positions it as a trusted partner in the healthcare sector, a commitment that we value and uphold for our stakeholders.
Chapters
- Strategic Partner of Choice for the Global Pharma and Biotech Industry
- On Track for Sustainable Profitable Growth and Value Creation
- Leveraging on Unique Business Opportunities to Drive Long-Term Growth
- The New Gerresheimer
- Bormioli Pharma Plastics complements our System and Solution Portfolio
- Systems Integration Enhancing Customer Value
- Q2 2024: Performance in-line with Previous Year
- P&D with continued margin improvement
- Reconciliation Q2 2024
- Free Cashflow Development as Expected
- Leveraging on Unique Business Opportunities to Drive Long-Term Growth
- Guidance
Resources
Host
Share
T&C:
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
Reviews for Gerresheimer AG Financial Results H1 2024 | Strong Growth & Strategic Investments
There are currently no reviews for Gerresheimer AG Financial Results H1 2024 | Strong Growth & Strategic Investments
(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG
Unlock the insights of top publicly listed companies with seat11a.com